Brought to you by 
Amgen and Roche to develop second-generation G-CSF; Amgen reacquires rights
18 Jun 2014
Executive Summary
Amgen and Roche will develop a second-generation G-CSF (granulocyte colony-stimulating factor) product for Europe and extend until 2010 their 1988 deal for sales of Neupogen, the original version.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com